DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Maxipime (Cefepime Hydrochloride) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Drug Interactions

Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics. Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.

OVERDOSAGE

Patients who receive an overdose should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid in the removal of cefepime from the body. Accidental overdosing has occurred when large doses were given to patients with impaired renal function. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, and neuromuscular excitability. (See WARNINGS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION.)

CONTRAINDICATIONS

MAXIPIME is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillins or other beta-lactam antibiotics.

REFERENCES

  1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically —Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December 1993.
  2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests —Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993.
  3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.


MAXIPIME® is a registered trademark of Bristol-Myers Squibb Company licensed exclusively in the US to EPI.
ADD-Vantage® is a registered trademark of Abbott Laboratories.
Normosol-R and Normosol-M are trademarks of Abbott Laboratories.
Aminosyn® is a registered trademark of Abbott Laboratories.
Inpersol is a trademark of Abbott Laboratories.
Clinitest® and Clinistix® are registered trademarks of Bayer HealthCare LLC.



Manufactured for:
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

Manufactured by:
Bristol-Myers Squibb, S.r.l.
04013 Sermoneta, Latina, ITALY
Or
Patheon UK Limited
Wiltshire SN3 5BZ, ENGLAND

Distributed by:
Elan Pharmaceuticals, Inc.
South San Francisco, CA 94080 USA

1256488A1
MXE90252
6001704/03
1115163A8
6001713/03
Rev March 2009


-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012